Meghana Keshavan covers biotech and contributes to The Readout newsletter.
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Today: We look at the unseemly side of scrutiny of Chinese biotech, have a SPAC for a bispecific maker, and Moderna’s mRNA ambitions enter a new phase despite years of setbacks.
Plus: Clive Meanwell sees AI’s biggest opportunity in the macro processes of biotech drug design, as opposed to the bespoke making of molecules.
To read the rest of this story subscribe to STAT+.
Meghana Keshavan covers biotech and contributes to The Readout newsletter.
Originally reported by STAT News.